《新股表现》昭衍新药(06127.HK)暗盘低开6%报142元
根据辉立交易平台显示,明天挂牌的昭衍新药(06127.HK)暗盘低开6%报142元欠承接,最低见138.2元,造139.1元,较上市价151元,低7.9%,成交8.2万股。
昭衍新药是内地专门从事新药药理毒理学研究及专注於药物非临床安全性评价领先合同研究组织,并正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段综合服务。是次来港上市共发售4,332.48万股H股,并已引入包括Lake Bleu Prime、Orbimed基金、中国结构调整基金及CPE Fund等11名基石投资者,合共认购近1,376万股;其中9%公开发售获309倍超购,已启动回拨机制占比增至36%,认购一手签率仅5%;股份以招股范围(133-151元)上限定价,料集资净额约62.86亿元,主要用作提高集团於苏州设施服务能力、增强集团於美国业务以迎合客户日益增长对Biomere所提供服务需求、用於在广州及重庆建设新设施、拓宽药物研发价值链上综合服务范围及拓展海外布局策略等。上市独家保荐人中信证券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.